GHz-Class NMR Opens New Scientific Research Window for Discoveries & Novel Insights in Functional Structural Biology & Diseas...
January 07 2021 - 7:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) today announced that three
world-leading institutions are now accelerating their research into
functional structural biology and human disease with new Bruker
ultra-high field nuclear magnetic resonance (NMR) spectrometers
installed in 2020. Novel GHz-class NMR technology enables advanced
research to obtain structural, functional and binding information
of intrinsically disordered proteins (IDPs), and of partially
structured proteins with key intrinsically disordered regions
(IDRs), at atomic resolution under near-physiological conditions.
For example, these new technological and methods capabilities now
accelerate research into viral-host interactions and viral
replication, as well as into proteins that are linked to
neurodegenerative diseases.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210107005212/en/
Professors Zweckstetter (left) and
Griesinger with the 1.2 GHz magnet at the MPI in Goettingen (Photo:
Business Wire)
The recent installation of a 1.2 GHz NMR spectrometer at the Max
Planck Institute for Biophysical Chemistry in Goettingen, has
already enabled their research teams to deliver new insights into
the SARS-CoV-2 nucleocapsid (N) protein, and it is set to aid the
deeper molecular understanding of Parkinson’s and Alzheimer’s
diseases.
Bruker's 1.2 GHz NMR magnets utilize a novel hybrid technology
with high-temperature superconductor (HTS) inserts in
low-temperature superconductor outer sections. The Ascend™ 1.2
GHz magnets are stable, homogenous, standard-bore (54 mm)
magnets suitable for high-resolution and solid-state NMR.
Using ultra-high field NMR, scientists at the Max Planck
Institute (MPI) and the German Center for Neurodegenerative
Diseases (DZNE) have shown that the SARS-CoV-2 N protein and host
ribonucleic acids (RNA) jointly condense into tiny droplets akin to
membraneless organelles, when the virus enters a host cell. This
fast liquid-liquid phase separation (LLPS) inside the cytoplasm of
the host cell is a characteristic capability of IDPs and IDRs, and
sheds new light on how the virus replicates, and offers new targets
for drug development.
Professor Christian Griesinger, Director and Scientific Member
at the Max Planck Institute for Biophysical Chemistry in
Goettingen, commented: “The new 1.2 GHz spectrometer will allow us
to characterize droplets and oligomers of IDPs that are key markers
in diseases such as COVID-19, neurodegenerative diseases and
cancer, and which cannot be studied using crystallography or
cryo-EM.”
Dr. Markus Zweckstetter, Professor at the University of
Goettingen and Group Leader at the German Center for
Neurodegenerative Diseases, added: “Our first experiments after the
installation of the new ultra-high field NMR system have focused on
the SARS-CoV-2 nucleocapsid N-protein that is of key relevance for
viral-host interactions and viral replication biology. The
liquid-like properties of viral replication machineries in
combination with the many intrinsically disordered regions of the
N-protein make this research ideally suited for GHz-class NMR.”
Dr. Falko Busse, President of the Bruker BioSpin Group stated:
“The fourth quarter acceptance at the Max Planck Institute follows
installations of two 1.2 GHz NMRs at CERM (University of Florence)
and at ETH Zuerich earlier in 2020. We are proud to provide
enabling technology for pushing the boundaries in functional
structural biology and advanced materials science.”
Dr. Busse continued: “We are also pleased that in December 2020,
we have received an order for a second Swiss 1.2 GHz system from a
consortium of the University of Zuerich, ETH Zuerich and the
Biozentrum of the University of Basel. For 2021, we anticipate the
installation of 4-5 GHz-class NMRs, as we have used 2020 to ramp
our capacity.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210107005212/en/
Investor Contact: Miroslava Minkova Director, Investor
Relations & Corporate Development T: +1 (978) 663-3660 x1479 E:
Investor.Relations@bruker.com
Media Contact: Thorsten Thiel, Ph. D. VP of Group
Marketing, Bruker BioSpin T: +49 (721) 5161–6500 E:
thorsten.thiel@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024